Analyst Price Targets — DNTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 10, 2026 7:53 pm | — | Jefferies | $132.00 | $76.42 | TheFly | Dianthus price target raised to $132 from $110 at Jefferies |
| May 11, 2026 12:04 pm | Gavin Clark-Gartner | Evercore ISI | $120.00 | $88.45 | TheFly | Dianthus price target lowered to $120 from $122 at Evercore ISI |
| May 6, 2026 12:48 pm | — | Raymond James | $125.00 | $87.83 | TheFly | Dianthus price target raised to $125 from $123 at Raymond James |
| April 8, 2026 8:38 pm | Andy Chen | Wolfe Research | $98.00 | $87.48 | TheFly | Dianthus initiated with an Outperform at Wolfe Research |
| March 9, 2026 7:56 pm | Maury Raycroft | UBS | $98.00 | $79.23 | TheFly | Dianthus price target raised to $98 from $81 at Jefferies |
| March 9, 2026 7:51 pm | Maury Raycroft | Jefferies | $98.00 | $79.23 | StreetInsider | Dianthus Therapeutics (DNTH) PT Raised to $98 at Jefferies |
| March 9, 2026 4:36 pm | — | Robert W. Baird | $132.00 | $79.23 | TheFly | Dianthus price target raised to $132 from $67 at Baird |
| March 9, 2026 4:04 pm | Swayampakula Ramakanth | H.C. Wainwright | $130.00 | $79.23 | TheFly | Dianthus price target raised to $130 from $47 at H.C. Wainwright |
| March 9, 2026 2:15 pm | Trevor Allred | Oppenheimer | $145.00 | $80.88 | StreetInsider | Dianthus Therapeutics (DNTH) PT Raised to $145 at Oppenheimer |
| March 9, 2026 2:14 pm | Alex Thompson | Stifel Nicolaus | $120.00 | $80.60 | StreetInsider | Dianthus Therapeutics (DNTH) PT Raised to $120 at Stifel |
Latest News for DNTH
NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees.
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28
Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP).
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DNTH.
U.S. House Trading
No House trades found for DNTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.